COVID-19 vaccine development has been halted by US pharmaceutical company Johnson & Johnson. A major plant of the company temporarily stopped vaccine production on Tuesday, according to the New York Times. It was only at the end of last year that vaccine production stopped in the Dutch city of Leiden. The report cites those who played a role in the decision.
Related Post – Best Luxury Hair Salons In Kolkata
J&J has continued to meet its vaccine delivery commitments, a company spokesperson said, without confirming or denying the report. The New York Times reported that the factory will restart COVID-19 production in “a few” months after it has been idle for a few months.
A J&J spokesperson said that the company currently has millions of doses of the COVID-19 vaccine. The company spokesperson said, “We will fulfill our contractual obligations toward African Union and the Covax facility.”
As a result, J&J expects COVID-19 vaccine sales to be $3 billion to $3.5 billion in 2022, far less than Pfizer’s forecast of $32 billion for the same period.
Due to its low-temperature requirement, the J&J vaccine has proven popular in developing countries, unlike many other alternatives. As well, the vaccine is originally offered as a single-shot vaccination.